Ovid Therapeutics, Inc., a privately held biopharmaceutical company focused on developing therapies for orphan diseases of the brain, today announced its participation in two upcoming investor conferences:
About Ovid Therapeutics, Inc.
Ovid Therapeutics, Inc. is a privately held, New York-based, biopharmaceutical company committed to transforming the lives of patients with orphan diseases of the brain. Ovid focuses on patients and their unmet medical needs. Using the significant operational, product development and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline, coupled with compelling research and development. Ovid has raised $80M in substantially oversubscribed financings led by Fidelity Management and Research Company and including Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates, Redmile Group, DoubleLine Equity Healthcare Fund, and Cormorant Asset Management, as well as additional blue chip mutual funds and leading life sciences investors.
For more information on Ovid, please visit http://www.ovidrx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160901005635/en/Business Wire
Last updated on: 01/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.